businesses across the United States, China, APAC, Europe, and Latin America. Deep expertise in FDA, NMPA, and CE-mark regulatory pathways, cross-border commercialization, execution turnarounds, and post-merger integration in complex, founder-led and PE-backed environments. I am most often brought in when companies face execution risk —moments where innovation, organization, regulatory exposure, or leadership alignment must be stabilized quickly and translated into durable business results. Over my career, I have repeatedly stepped into situations requiring decisive action under ambiguity, strengthening credibility with regulators, customers, boards, and investors while restoring momentum and performance. Most recently, I served as President & CEO of a China-based structural heart company, where I led global expansion across Europe, Latin America, Southeast Asia, and broader APAC markets. During this period, I reduced net losses by nearly 90%, delivered sustained revenue growth, executed multiple regulatory and commercial launches, and integrated an acquired cardiac business into a broader cardiovascular platform. I led the company’s restructuring and international expansion efforts, aligning and directing the leadership team, with shareholders, board members, and investors informed through formal governance processes. Earlier in my career, I was repeatedly recruited into roles where teams, programs, or portfolios were underperforming—turning around struggling R&D, technology, and product organizations, rebuilding operating structures, and translating advanced technology into scalable commercial outcomes at companies including Edwards Lifesciences, Spectranetics, and Abbott (formerly Guidant). My experience spans Class II and Class III medical devices, structural heart and vascular interventions, and global product development and launch across highly regulated markets. Today, I work closely with investors, boards, and founders on execution-critical situations, particularly where companies are navigating growth inflection points, regulatory complexity, cross- border expansion, integration, or leadership transition. I am most effective in senior operating roles—CEO, President, COO, or CTO —where technology leadership, execution discipline, and business outcomes must be tightly aligned, as well as in portfolio operations or transformation leadership roles requiring hands-on accountability and judgment when timing and outcomes matter. Experience Work hands-on with medical device portfolio companies to support global expansion, regulatory strategy, and operational scaling. Partner with CEOs and leadership teams to address execution gaps, accelerate commercialization, and prepare businesses for next-stage growth.

Advanced at organization with primary focus on designing and implementing strategic plans for global market expansion in structural heart market. Direct and provide expert guidance on market analysis, manage product portfolio lifecycle, and optimize profitability by addressing unmet customer needs and controlling expenses. Present strategic investment recommendations to executive committees and serve as board observer for US-based startup, collaborating on technical strategy and innovative product development. • Created new revenue opportunities by leading acquisition of cardiac products company, integrating employees, and achieving NMPA approval to launch products in China, with high potential for commercialization in US, Europe, and other global markets. • Increased YoY revenue growth by 35% in China and 62% internationally by expanding company's global presence, securing NMPA and CE approvals, and opening 5 new markets in 2023 with plans for 15 more in 2024.

Revamped and transformed R&D strategy and product development, improving lifecycle management and accelerating milestone achievements. Reorganized 90-member team to support 13 new product development projects, identified and resolved development barriers, and defined clear resource allocation and objectives. Expanded global reach by establishing relationships with international KOLs, assessed external partnership opportunities, and influenced high-performing, innovative environment, resulting in 4 product approvals. • Elevated R&D support for cross-functional teams by restructuring organizational and development processes, securing compassionate use exemptions for life-saving devices in developing countries, and advancing clinical trials for investigational products. • Built an upstream marketing team to gather and analyze customer data, identify market needs/trends, and ensure delivery of clear requirements to product development, executing customer-focused solutions and new market creation.

(9 years 10 months) Directed R&D strategy and early-stage development for transcatheter valve programs at leading global medical device company. Implemented design improvements, developed 2 TAVR products, and turned around struggling program by resolving clinical study challenges and unifying team. Led cross- functional product development teams including members from R&D, clinical, regulatory, supply chain management, marketing, and quality assurance. • Achieved outstanding clinical trial results in Europe for first-in-industry electro-mechanical delivery system by restructuring R&D leadership, resolving design issues, and driving design, development, and commercialization of industry-leading valve system. • Created 2 internal CoEs to develop innovative materials, accelerating iteration cycle and expanding prototype production to over 25,000 components annually.

(4 years 3 months) Established and directed R&D organization, managing $8M budget and leading 24-member cross-functional team. Implemented advanced project management techniques to oversee project scope, budget management, reporting, and problem-solving. • Implemented cutting-edge project management techniques to oversee project scope, budget management, reporting, and problem-solving, driving successful development and commercialization of disposable Class II & III medical devices.